Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis

Background & Aims: Treatment with non-selective beta-blockers (NSBBs) reduces the risk of ascites, which is the most common decompensating event in cirrhosis. This study aimed to assess the ability of a serum microRNA (miRNA) signature to predict ascites formation and the hemodynamic respons...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ana Garcia Garcia de Paredes, Càndid Villanueva, Carolina Blanco, Joan Genescà, Nicolo Manicardi, Juan Carlos Garcia-Pagan, Jose Luis Calleja, Carlos Aracil, Rosa M. Morillas, Maria Poca, Beatriz Peñas, Salvador Augustin, Juan G. Abraldes, Eldimar Alvarado, Félix Royo, Maria Laura Garcia-Bermejo, Juan Manuel Falcon-Perez, Rafael Bañares, Jaime Bosch, Jordi Gracia-Sancho, Agustin Albillos
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Ascites beta-blockers cirrhosis microRNA portal hypertension Diseases of the digestive system. Gastroenterology RC799-869
Acceso en línea:	https://doaj.org/article/59ab79c9a0de4e2da9fed5699a961c6b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:59ab79c9a0de4e2da9fed5699a961c6b
record_format	dspace
spelling	oai:doaj.org-article:59ab79c9a0de4e2da9fed5699a961c6b2021-11-20T05:11:57ZSerum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis2589-555910.1016/j.jhepr.2021.100368https://doaj.org/article/59ab79c9a0de4e2da9fed5699a961c6b2021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2589555921001440https://doaj.org/toc/2589-5559Background & Aims: Treatment with non-selective beta-blockers (NSBBs) reduces the risk of ascites, which is the most common decompensating event in cirrhosis. This study aimed to assess the ability of a serum microRNA (miRNA) signature to predict ascites formation and the hemodynamic response to NSBBs in compensated cirrhosis. Methods: Serum levels of miR-452-5p, miR-429, miR-885-5p, miR-181b-5p, and miR-122-5p were analyzed in patients with compensated cirrhosis (N = 105). Hepatic venous pressure gradient (HVPG) was measured at baseline, after intravenous propranolol, and 1 year after randomization to NSBBs (n = 52) or placebo (n = 53) (PREDESCI trial). miRNAs were analyzed at baseline and at 1 year. Results: Nineteen patients (18%) developed ascites, of whom 17 developed ascites after 1 year. miR-181b-5p levels at 1 year, but not at baseline, were higher in patients that developed ascites. The AUC of miR-181b-5p at 1 year to predict ascites was 0.7 (95% CI 0.59–0.78). miR-429 levels were lower at baseline in acute HVPG responders to NSBBs (AUC 0.65; 95% CI, 0.53–0.76), but levels at baseline and at 1 year were not associated with the HVPG response to NSBBs at 1 year. Conclusions: Serum miR-181b-5p is a promising non-invasive biomarker to identify patients with compensated cirrhosis at risk of ascites development. Lay summary: Ascites marks the transition from the compensated to decompensated stage in cirrhosis and indicates a worsening in prognosis. There are currently no easily accessible tools to identify patients with compensated cirrhosis at risk of developing ascites. We evaluated the levels of novel molecules termed microRNAs in the blood of patients with compensated cirrhosis and observed that miR-181b-5p can predict which patients are going to develop ascites.Ana Garcia Garcia de ParedesCàndid VillanuevaCarolina BlancoJoan GenescàNicolo ManicardiJuan Carlos Garcia-PaganJose Luis CallejaCarlos AracilRosa M. MorillasMaria PocaBeatriz PeñasSalvador AugustinJuan G. AbraldesEldimar AlvaradoFélix RoyoMaria Laura Garcia-BermejoJuan Manuel Falcon-PerezRafael BañaresJaime BoschJordi Gracia-SanchoAgustin AlbillosElsevierarticleAscitesbeta-blockerscirrhosismicroRNAportal hypertensionDiseases of the digestive system. GastroenterologyRC799-869ENJHEP Reports, Vol 3, Iss 6, Pp 100368- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ascites beta-blockers cirrhosis microRNA portal hypertension Diseases of the digestive system. Gastroenterology RC799-869
spellingShingle	Ascites beta-blockers cirrhosis microRNA portal hypertension Diseases of the digestive system. Gastroenterology RC799-869 Ana Garcia Garcia de Paredes Càndid Villanueva Carolina Blanco Joan Genescà Nicolo Manicardi Juan Carlos Garcia-Pagan Jose Luis Calleja Carlos Aracil Rosa M. Morillas Maria Poca Beatriz Peñas Salvador Augustin Juan G. Abraldes Eldimar Alvarado Félix Royo Maria Laura Garcia-Bermejo Juan Manuel Falcon-Perez Rafael Bañares Jaime Bosch Jordi Gracia-Sancho Agustin Albillos Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis
description	Background & Aims: Treatment with non-selective beta-blockers (NSBBs) reduces the risk of ascites, which is the most common decompensating event in cirrhosis. This study aimed to assess the ability of a serum microRNA (miRNA) signature to predict ascites formation and the hemodynamic response to NSBBs in compensated cirrhosis. Methods: Serum levels of miR-452-5p, miR-429, miR-885-5p, miR-181b-5p, and miR-122-5p were analyzed in patients with compensated cirrhosis (N = 105). Hepatic venous pressure gradient (HVPG) was measured at baseline, after intravenous propranolol, and 1 year after randomization to NSBBs (n = 52) or placebo (n = 53) (PREDESCI trial). miRNAs were analyzed at baseline and at 1 year. Results: Nineteen patients (18%) developed ascites, of whom 17 developed ascites after 1 year. miR-181b-5p levels at 1 year, but not at baseline, were higher in patients that developed ascites. The AUC of miR-181b-5p at 1 year to predict ascites was 0.7 (95% CI 0.59–0.78). miR-429 levels were lower at baseline in acute HVPG responders to NSBBs (AUC 0.65; 95% CI, 0.53–0.76), but levels at baseline and at 1 year were not associated with the HVPG response to NSBBs at 1 year. Conclusions: Serum miR-181b-5p is a promising non-invasive biomarker to identify patients with compensated cirrhosis at risk of ascites development. Lay summary: Ascites marks the transition from the compensated to decompensated stage in cirrhosis and indicates a worsening in prognosis. There are currently no easily accessible tools to identify patients with compensated cirrhosis at risk of developing ascites. We evaluated the levels of novel molecules termed microRNAs in the blood of patients with compensated cirrhosis and observed that miR-181b-5p can predict which patients are going to develop ascites.
format	article
author	Ana Garcia Garcia de Paredes Càndid Villanueva Carolina Blanco Joan Genescà Nicolo Manicardi Juan Carlos Garcia-Pagan Jose Luis Calleja Carlos Aracil Rosa M. Morillas Maria Poca Beatriz Peñas Salvador Augustin Juan G. Abraldes Eldimar Alvarado Félix Royo Maria Laura Garcia-Bermejo Juan Manuel Falcon-Perez Rafael Bañares Jaime Bosch Jordi Gracia-Sancho Agustin Albillos
author_facet	Ana Garcia Garcia de Paredes Càndid Villanueva Carolina Blanco Joan Genescà Nicolo Manicardi Juan Carlos Garcia-Pagan Jose Luis Calleja Carlos Aracil Rosa M. Morillas Maria Poca Beatriz Peñas Salvador Augustin Juan G. Abraldes Eldimar Alvarado Félix Royo Maria Laura Garcia-Bermejo Juan Manuel Falcon-Perez Rafael Bañares Jaime Bosch Jordi Gracia-Sancho Agustin Albillos
author_sort	Ana Garcia Garcia de Paredes
title	Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis
title_short	Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis
title_full	Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis
title_fullStr	Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis
title_full_unstemmed	Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis
title_sort	serum mir-181b-5p predicts ascites onset in patients with compensated cirrhosis
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/59ab79c9a0de4e2da9fed5699a961c6b
work_keys_str_mv	AT anagarciagarciadeparedes serummir181b5ppredictsascitesonsetinpatientswithcompensatedcirrhosis AT candidvillanueva serummir181b5ppredictsascitesonsetinpatientswithcompensatedcirrhosis AT carolinablanco serummir181b5ppredictsascitesonsetinpatientswithcompensatedcirrhosis AT joangenesca serummir181b5ppredictsascitesonsetinpatientswithcompensatedcirrhosis AT nicolomanicardi serummir181b5ppredictsascitesonsetinpatientswithcompensatedcirrhosis AT juancarlosgarciapagan serummir181b5ppredictsascitesonsetinpatientswithcompensatedcirrhosis AT joseluiscalleja serummir181b5ppredictsascitesonsetinpatientswithcompensatedcirrhosis AT carlosaracil serummir181b5ppredictsascitesonsetinpatientswithcompensatedcirrhosis AT rosammorillas serummir181b5ppredictsascitesonsetinpatientswithcompensatedcirrhosis AT mariapoca serummir181b5ppredictsascitesonsetinpatientswithcompensatedcirrhosis AT beatrizpenas serummir181b5ppredictsascitesonsetinpatientswithcompensatedcirrhosis AT salvadoraugustin serummir181b5ppredictsascitesonsetinpatientswithcompensatedcirrhosis AT juangabraldes serummir181b5ppredictsascitesonsetinpatientswithcompensatedcirrhosis AT eldimaralvarado serummir181b5ppredictsascitesonsetinpatientswithcompensatedcirrhosis AT felixroyo serummir181b5ppredictsascitesonsetinpatientswithcompensatedcirrhosis AT marialauragarciabermejo serummir181b5ppredictsascitesonsetinpatientswithcompensatedcirrhosis AT juanmanuelfalconperez serummir181b5ppredictsascitesonsetinpatientswithcompensatedcirrhosis AT rafaelbanares serummir181b5ppredictsascitesonsetinpatientswithcompensatedcirrhosis AT jaimebosch serummir181b5ppredictsascitesonsetinpatientswithcompensatedcirrhosis AT jordigraciasancho serummir181b5ppredictsascitesonsetinpatientswithcompensatedcirrhosis AT agustinalbillos serummir181b5ppredictsascitesonsetinpatientswithcompensatedcirrhosis
_version_	1718419541267054592

Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis

Ejemplares similares